Schering Rebetron Hepatitis C Therapy Five Year Phase IV Data Requested
Schering-Plough will submit five-year follow-up data from its four pivotal trials of Rebetron as part of its Phase IV commitments to FDA. The combination therapy of Schering's Intron A (interferon alfa-2b) injection and Rebetol (Schering/ICN's ribavirin) for hepatitis C was approved June 3.
You may also be interested in...
Bristol-Myers Squibb's submission of two separate NDAs for the combination use of UFT and leucovorin appears to be a new filing and approval strategy for the development of bundled multi-ingredient products.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011